Levine L R, McCain E
J Infect Dis. 1978 May;137 Suppl:S125-S132. doi: 10.1093/infdis/137.supplement.s125.
Clinical and bacteriologic results are reported for 80 patients treated with 1.5--12 g of cefamandole daily for a variety of infections caused by Enterobacter and indole-positive Proteus, organisms that have been resistant to most available cephalosporins. Of 45 patients with infections due to Enterobacter, 41 (91%) had satisfactory clinical responses; 36 were bacteriologic successes, and six cases of complicated urinary tract infections relapsed. Of 37 patients with infections due to indole-positive Proteus, 28 (88%) were clinical successes and 30 (81%) were bacteriologic successes. Fourteen cases of complicated urinary tract infection relapsed. Of 104 patients in whom the drug was evaluated for safety, use of cefamandole was discontinued in five; nine adverse reactions were considered drug-related. A summary of published in vitro data shows that the majority of strains of these organisms were susceptible to cefamandole at concentrations achievable in the serum. Minimal inhibitory concentrations are variable, and there is a significant inoculum effect, the clinical significance of which has not been determined.
报告了80例患者的临床和细菌学结果，这些患者因肠杆菌属和吲哚阳性变形杆菌引起的各种感染，每天接受1.5 - 12克头孢孟多治疗，这些细菌对大多数现有头孢菌素耐药。45例因肠杆菌属感染的患者中，41例（91%）有满意的临床反应；36例细菌学治疗成功，6例复杂性尿路感染复发。37例因吲哚阳性变形杆菌感染的患者中，28例（88%）临床治疗成功，30例（81%）细菌学治疗成功。14例复杂性尿路感染复发。在104例评估了该药物安全性的患者中，5例停用了头孢孟多；9例不良反应被认为与药物有关。已发表的体外数据总结表明，这些细菌的大多数菌株在血清可达到的浓度下对头孢孟多敏感。最低抑菌浓度各不相同，且存在显著的接种量效应，其临床意义尚未确定。
